Skip to main content

Naloxone startup pursues FDA approval for over-the-counter swab

By The Wall Street Journal  
   December 01, 2022

FDA has encouraged companies to pursue nonprescription status for opioid-reversal drugs.

Full story


Get the latest on healthcare leadership in your inbox.